Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) is a rare complication following hematopoietic stem cell transplantation (HSCT) with an incidence of approximately 1%. 1 Major risk factors for development of PTLD include unrelated or human leukocyte antigen (HLA)-mismatched-related donor transplantation, T-cell depletion of the graft, use of antithymocyte globulin (ATG), grade II-IV acute graft-versus-host disease (GVHD) and intense immunosuppression. 2 Chronic GVHD is the main risk factor for late-onset PTLD. 3 Isolated central nervous system (CNS) involvement with EBV-associated PTLD is an exceedingly rare complication after HSCT. We report here the development of isolated CNS PTLD, with negative-unfractionated whole blood and cerebrospinal fluid (CSF) EBV PCR, in a patient with chronic myeloid leukemia (CML) following a HLAmismatched HSCT conditioned with busulfan, fludarabine and ATG.
A 49-year-old white man with CML, who progressed after 2 years of treatment with imatinib mesylate, entered accelerated phase while taking AMN107 (Nilotinib). He underwent nonmyeloablative peripheral blood HSCT from a two allele (HLA-B and HLA DRB1) mismatched unrelated female donor. Both donor and recipient were EBV positive. Following reduced-intensity conditioning with intravenous busulfan (0.8 mg/kg every 6 h, days À4 and À3), fludarabine (30 mg/m 2 /day, days À7, À6, À5, À4 and À3) and ATG (2.5 mg/kg/day, days À4, À3 and À2), 2.56 Â 10 6 CD34 þ cells/kg of recipient were infused. GVHD prophylaxis consisted of methotrexate (5 mg/m 2 on days þ 1, þ 3, þ 6 and þ 11) and tacrolimus (starting day À2). The patient engrafted (ANC4500/mm 3 ) on day þ 14 after the transplant. On day þ 23, the patient was started on prednisone (1 mg/kg/day) and mycophenolate mofetil for grade II acute GVHD. Engraftment studies (day þ 37) confirmed complete donor chimerism. The patient's immunosuppression was tapered to 10 mg prednisone daily and mycophenolate mofetil 500 mg daily by day þ 100.
On day þ 108, the patient developed fever, confusion and ataxia. Magnetic resonance imaging (MRI) of the brain showed multiple ring enhancing ( Figure 1 ) lesions involving both cerebellar and cerebral hemispheres, midbrain and basal ganglia with associated vasogenic edema. Immunosuppressive medications were discontinued. CSF examination revealed pleocytosis of 33/mm 3 (93% lymphocytes), glucose 72 mg/dl and protein of 136 mg/dl. Bacterial, fungal, viral and parasitic infections were excluded by appropriate testing. CSF-flow cytometry was unremarkable with no B cells and normal CD4/CD8 þ T-cell ratio. Serum and CSF reverse transcriptase-polymerase chain reaction (RT-PCR) for bcr/abl translocation and EBV DNA were both negative. On day þ 122, the patient underwent craniotomy and resection of a 4.3 Â 2.9 Â 1.8 cm right-frontal lobe ring enhancing lesion. Microscopic examination revealed a moderately cellular neoplasm consisting of atypical lymphoid cells with pleomorphic nuclei, prominent nucleoli and marked angiocentricity. Immunohistochemical studies demonstrated that the atypical lymphoid cells were positive for CD20, CD79a, CD30, CD43 and l light chain. CD3 and CD5 were positive in scattered cells. Lymphoid cells were positive for latent membrane protein 1 and EBV nuclear antigen 2. In situ hybridization studies showed EBV RNA in the nuclei of atypical lymphoid cells. These findings established the diagnosis of EBV-associated lymphoproliferative disorder. Real-time PCR for EBV DNA on unfractionated whole blood and CSF on two separate occasions (8 weeks apart) were negative. CT scans of the chest, abdomen and pelvis showed no evidence of lymphadenopathy. Bone marrow biopsy showed no evidence of CML. In situ hybridization for EBV-encoded RNA on bone marrow specimen was positive; however, immunohistochemistry and flow cytometry showed no evidence of B-cell lymphoma. Two days after craniotomy, the patient developed grade IV GVHD (44l diarrhea/day) complicated by acute tubular necrosis. We treated the patient with whole brain external beam radiation (3600 cGy in 18 fractions) and methylprednisolone 2 mg/kg/day. Repeat brain MRI after 10 fractions of radiation showed a partial response. The patient unfortunately died on day þ 169 because of overwhelming Gram-negative sepsis, before response to complete course of radiation could be assessed.
Incidence of PTLD after allogeneic HSCT is approximately 1%; however, in patients with three or more risk factors the incidence may be as high as 22%. 3 Isolated CNS involvement with PTLD after HSCT is exceedingly rare with only four reports in the medical literature. [4] [5] [6] [7] Monitoring of serum EBV viral loads by quantitative PCR has been shown to correlate with the development of EBV-associated PTLD. Van Esser et al. 8 showed that plasma EBV DNA PCR not only quantitatively predicted the development of EBV-associated PTLD but a viral load of o1000 genome equivalents/ml had a negative predictive value of 100% in T-cell-depleted HSCT patients. In our patient, repeated testing with real-time PCR on peripheral blood and CSF failed to show any evidence of EBV reactivation. The present case and the earlier report by Terasawa et al. 7 demonstrate that primary CNS EBVassociated PTLD should remain in the differential of patients presenting with symptoms referable to a CNS lesion despite negative EBV PCR on peripheral blood and CSF.
Treatment of isolated CNS PTLD has rarely been successful (Table 1) . Rituximab has shown promising activity in systemic PTLD, but Pakakasama et al. 6 reported no response of primary CNS PTLD to rituximab therapy, suggesting that CNS penetration might be poor. In contrast, Nozzoli et al. 4 reported complete response of CNS PTLD with intravenous rituximab, cidofovir and intrathecal methotrexate and methylprednisolone in a patient with leptomeningeal disease without focal brain lesions. It is not clear whether the same response could be obtained with rituximab alone. We decided not to use rituximab because of acute renal failure in our patient and lack of data demonstrating efficacy of rituximab in CNS PTLD. Donor lymphocyte infusion carries the risk of causing GVHD and has not been shown to be effective in CNS PTLD. 4 Pakakasama et al. 6 reported favorable response of CNS PTLD to a combination of EBV-specific cytotoxic T cells (EBV-CTL) with hydroxyurea. EBV-CTLs are, however, not widely available and can take months to generate. Moreover, their infusion may exacerbate GVHD. 9 Our patient had grade IV GVHD at the time of PTLD diagnosis, and both DLI and EBV-CTL did not appear to be safe options. Whole-brain radiation is the most effective therapy for isolated CNS PTLD following solid organ transplantation. 10 To our knowledge, this is the first case of isolated CNS PTLD following nonmyeloablative HSCT, and the first such case treated with wholebrain radiation. In conclusion, primary CNS PTLD should 
